Skip Navigation



PEDS Advance Access published online on December 2, 2008
Protein Engineering Design and Selection, doi:10.1093/protein/gzn070
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
22/3/189    most recent
gzn070v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Gabbard, J.
Right arrow Articles by Bradbury, A.R.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gabbard, J.
Right arrow Articles by Bradbury, A.R.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

A humanized anti-M2 scFv shows protective in vitro activity against influenza

J. Gabbard1, N. Velappan2, R. Di Niro3, J. Schmidt2, C.A. Jones1, S.M. Tompkins1,4 and A.R.M. Bradbury2,4

1Department of Infectious Diseases, Animal Health Research Center, Influenza Pathogenesis and Immunology Research Center, College of Veterinary Medicine, University of Georgia, 111 Carlton Street, Building 1077, Athens, GA 30602-1563 2B Division, Los Alamos National Laboratory, TA-43, HRL-1, Los Alamos, NM 87545, USA 3Centre for Immune Regulation, Institute of Immunology, Rikshospitalet, University of Oslo, Sognsvannsveien 20, N-0027 Oslo, Norway

4 To whom correspondence should be addressed. E-mail: smt{at}uga.edu (S.M.T.); amb{at}lanl.gov (A.R.M.B.)

M2 is one of the most conserved influenza proteins, and has been widely prospected as a potential universal vaccine target, with protection predominantly mediated by antibodies. In this paper we describe the creation of a humanized single chain Fv from 14C2, a potent monoclonal antibody against M2. We show that the humanized scFv demonstrates similar activity to the parental mAb: it is able to recognize M2 in its native context on cell surfaces and is able to show protective in vitro activity against influenza, and so represents a potential lead antibody candidate for universal prophylactic or therapeutic intervention in influenza.

Received October 24, 2008; revised October 24, 2008; accepted October 27, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.